Skip to main content
. Author manuscript; available in PMC: 2019 Jan 22.
Published in final edited form as: Cancer Discov. 2018 Jan 4;8(3):288–303. doi: 10.1158/2159-8290.CD-16-1406

Figure 6.

Figure 6.

Schematic showing potential clinical applications of digital CTC analysis in metastatic and localized prostate cancer, including prediction of resistance to AR-targeted therapy in mCRPC (CTCM Score), and risk of microscopic dissemination to seminal vesicles or lymph nodes in clinically localized prostate cancer (CTCL Score).